

**Sachs Associates present**

# 2<sup>nd</sup> LONDON BIOTECH INVESTMENT FORUM

**22 June 2006, The London Stock Exchange**

<b>AGENDA, THURSDAY 22 JUNE</b>	
<b>8.00</b>	<b>Registration</b>
<b><u>THEATRE</u></b>	
<b>9.15 - 9.30</b>	<b>Chairman's Opening Welcome</b>  Anthony Warnock-Smith, Partner European Life Sciences, <b>Morgan Lewis</b>
<b>9.30 - 10.40</b>	<b>The changing Pharma – Biotech interface</b>  <b>Chair:</b> Stephanie Léouzon, Managing Director, European Healthcare, <b>Credit Suisse First Boston</b>  <b>Panellists:</b> Kenneth D Noonan, Ph.D., Partner, <b>L.E.K. Consulting</b> Genghis Lloyd-Harris, MD, PhD, Partner, <b>Abingworth Management</b> Tamar Howson, Senior Vice President, Corporate Development, <b>Bristol-Myers Squibb</b> Dr Axel Polack, Venture Partner, <b>TVM Capital</b>
<b>10.40</b>	<b>Coffee Break</b>
<b>11.10 - 13.00</b>	<b>Small-Cap Listed Company Presentations</b>
<b>11.10</b>	<b>ROOM: Theatre</b> Chair: Dimitri Dimitriou, <b>DyoDelta Biosciences</b>
<b>11.10</b>	<b>ROOM: Forum</b> Chair: Peter Kalinka, <b>Accelsiors Group</b>
<b>11.15</b>	Dr Steven Powell, Chief Executive Officer, <b>Plethora Solutions</b>
<b>11.15</b>	Dr Dai Chaplin, Head of Research & Development, <b>Oxigene</b>
<b>11.30</b>	Simon Kerr, Commercial Director, <b>CeNeS Pharmaceuticals</b>
<b>11.30</b>	Dr. Ulrich Dauer, Chief Executive Officer, <b>4SC</b>
<b>11.45</b>	Dr Paul Ashton, Director of Strategy, <b>pSivida</b>
<b>11.45</b>	Dr Fahar Merchant, President & CEO, <b>Protox Therapeutics</b>
<b>12.00</b>	Tom Williams, Chief Executive Officer, <b>BioDiem</b>
<b>12.00</b>	Michael Hunt, Chief Executive Officer, <b>ReNeuron</b>
<b>12.15</b>	Questions to panellists
<b>12.15</b>	Questions to panellists

<b>12.30</b>	<b>Lunch</b>	
<b>13.45</b>	<b>Capital Finance Panel</b>	
	<b>Chair:</b> Anthony Warnock-Smith, Partner European Life Sciences, <b>Morgan Lewis</b>	
	<b>Panellists:</b> Nesson Bermingham, Principal, <b>Atlas Venture</b> Andrew Wallace, UK Main Market Product Manager, <b>London Stock Exchange</b> Dr Brian Hargreaves, Sector Partner – Healthcare, <b>3i</b> Denise Pollard-Knight, Chief Executive Officer, <b>Nomura Phase4 Ventures</b>	
<b>14.30 - 17.00</b>	<b>Sector Workshops: Venture Funded Early – Mid Stage Biotech Companies</b>	
<b>14.35</b>	<b>ROOM: Theatre</b> Chair: Dr Chris Gardner, <b>Citigate Dewe Rogerson</b>	<b>ROOM: Forum</b> Chair: Douglas Pretsell, <b>Northbank Communications</b>
<b>14.40</b>	Joerg Scheidle, Managing Director & CFO, <b>immatics biotechnologies</b>	Nick Landekic, President & CEO, <b>PolyMedix</b>
<b>14.55</b>	Dr Martin Buckland, Chief Business Officer, <b>Astex Therapeutics</b>	Dr Mark Schwartz, President & CEO, <b>Bayhill Therapeutics</b>
<b>15.10</b>	Dr Clive Dix, Chief Executive Officer, <b>PowderMed</b>	Dr Kirsten Drejer, Co-Founder & Chief Executive Officer, <b>Symphogen</b>
<b>15.25</b>	Dr Bernhard Sixt, Co-Founder & Chief Executive Officer, <b>Agendia</b>	Dr Andre Choulika, Director & CEO, <b>Collectis</b>
<b>15.40</b>	Dr Keith McCullagh, President & Chief Executive Officer, <b>Santaris Pharma</b>	Dr William Garner, Managing Director & CEO, <b>Inverseon</b>
<b>15.55</b>	Dr Johanna Holldack, Chief Executive Officer, <b>BOREAN Pharma</b>	David King, Chief Executive Officer, <b>BioRexis</b>
<b>16.10</b>	Dr Michael Moore, Chief Executive Officer, <b>PIramed</b>	Dr Paul Reid, Director & CSO, <b>Celtic Biotech</b>
<b>16.25</b>	Dr Steven Burton, Chief Executive Officer, <b>ProMetic Biosciences</b>	Dr Robert Burns, President & Chief Executive Officer, <b>Celldex</b>
<b>16.40</b>	Questions to panellists and close of conference	Questions to panellists and close of conference